Format
Sort by

Send to

Choose Destination

Search results

Items: 8

1.

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.

Hadji P, Jackisch C, Bolten W, Blettner M, Hindenburg HJ, Klein P, König K, Kreienberg R, Rief W, Wallwiener D, Zaun S, Harbeck N.

Ann Oncol. 2014 Feb;25(2):372-7. doi: 10.1093/annonc/mdt513.

2.

Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology.

Richter R, Oskay-Oezcelik G, Chekerov R, Pilger A, Hindenburg HJ, Sommer H, Camara O, Keil E, Einenkel J, Sehouli J.

Anticancer Res. 2012 Sep;32(9):3969-76.

PMID:
22993346
3.

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.

John M, Hinke A, Stauch M, Wolf H, Mohr B, Hindenburg HJ, Papke J, Schlosser J; FAKT Study Group..

BMC Cancer. 2012 May 4;12:165.

4.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO)..

Anticancer Res. 2008 Mar-Apr;28(2B):1329-34.

5.

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N.

J Clin Oncol. 2007 Aug 1;25(22):3246-50.

PMID:
17577021
6.

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.

Sehouli J, Oskay-Ozcelik G, Kühne J, Stengel D, Hindenburg HJ, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)..

Ann Oncol. 2006 Jun;17(6):957-61.

7.

[The German Guideline Clearinghouse on Breast Cancer: the need for frequent updating of breast cancer guidelines requires effective guideline updating procedures].

Weingart O, Sonntag D, Trapp H, Bartsch HH, Baumeister RG, Goerke K, Giersiepen K, Hindenburg HJ, Ming K, Schulz-Wendtland R, Störkel S, Kober T, Thole H, Kirchner H, Ollenschläger G; Guideline clearing house on breast cancer..

Z Arztl Fortbild Qualitatssich. 2004 Aug;98(5):403-11. German.

PMID:
15487388
8.

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W; NOGGO study group..

Ann Oncol. 2002 Nov;13(11):1749-55.

Items per page

Supplemental Content

Loading ...
Support Center